320.23MMarket Cap-4595P/E (TTM)
2.180High2.105Low675.23KVolume2.110Open2.130Pre Close1.45MTurnover0.47%Turnover RatioLossP/E (Static)148.26MShares3.26052wk High-34.84P/B310.67MFloat Cap1.46052wk Low--Dividend TTM143.83MShs Float27.983Historical High--Div YieldTTM3.52%Amplitude0.970Historical Low2.142Avg Price1Lot Size
Xeris Pharmaceuticals Stock Forum
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma announced positive topline results from its Phase 2 study of XP-8121, a once-weekly subcutaneous levothyroxine (SC) formulation. The study showed that XP-8121 provides predictable bioavailability and sustained levothyroxine levels, achieving normalized TSH/T4 levels with 45% less drug...
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones
No comment yet